Topics

Exondys 51 is $300M a yr drug and no one knows if it works. That’s odd. Sarepta promised FDA to conduct a trial to confirm Exondys’ treatment benefit but is 3-4 yrs behind schedule. Meantime, $SRPT profits. I wrote about this: https://www.statnews.com

10:45 EDT 15 Aug 2019 | STAT

Exondys 51 is $300M a yr drug and no one knows if it works. That’s odd. Sarepta promised FDA to conduct a trial to confirm Exondys’ treatment benefit but is 3-4 yrs behind schedule. Meantime, profits. I wrote about this: https://www.statnews.com/2019/08/15/sarepta-duchenne-drug-questions-exondys-51/ …

Original Article: Exondys 51 is $300M a yr drug and no one knows if it works. That’s odd. Sarepta promised FDA to conduct a trial to confirm Exondys’ treatment benefit but is 3-4 yrs behind schedule. Meantime, $SRPT profits. I wrote about this: https://www.statnews.com

NEXT ARTICLE

More From BioPortfolio on "Exondys 51 is $300M a yr drug and no one knows if it works. That’s odd. Sarepta promised FDA to conduct a trial to confirm Exondys’ treatment benefit but is 3-4 yrs behind schedule. Meantime, $SRPT profits. I wrote about this: https://www.statnews.com"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...